Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics also grew despite pricing reforms in China. Significant regulatory approvals and positive clinical trial data support Roche's outlook to increase sales and earnings in 2026, with plans to launch up to 20 new medicines by 2030. The company confirmed its mid-single-digit sales growth and high single-digit earnings per share growth targets for the full year.
Roche's third-quarter sales momentum is noted alongside Pluang's Health sector market snapshot as of Oct 22, 2026 12:11 WIB: Among 150 priced Health-sector US stocks, 70 rose and 79 fell today. Key movers include AVTR at USD 17.40 with a 4.69% increase and a typical hold time of 9 days, NVAX at USD 10.90 down 4.64% with 99% sell order activity and a typical hold time of 59 days, and ROIV at USD 36.52 up 4.58% with 100% buy order activity and a typical hold time of 6 days. The most notable figure is the 100% buy order activity for ROIV.
Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, a key infrastructure initiative aimed at strengthening the electricity network's security and resilience in the Balearic Islands. ...
Ipsen reported a 24.6% sales growth at constant exchange rates for the first nine months of 2026, driven by strong performance in Oncology, Rare Disease, and Neuroscience segments. The company upgraded its full-year sales growth guidance to around 23...
Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, aimed at enhancing the electricity network's security and resilience in the Balearic Islands. The project includes a six-month eng...
Nexans posted a 10.1% increase in revenue to €4.95 billion for the first nine months of 2026, driven by strong organic growth in its electrification segments PWR-Grid and PWR-Connect. The company successfully integrated Republic Wire in the US and co...
Ipsen reported a 24.6% revenue increase at constant exchange rates for the first nine months of 2026, driven by strong sales in oncology, rare diseases, and neurosciences. The company raised its full-year sales growth forecast to about 23% and expect...
